2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
70 recruiting
4
Rare Diseases
across 7 areas
0
News (30d)
Quiet
Vico Therapeutics B.V. is a company with 2 orphan drug designations across 4 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| Huntington disease | an antisense oligonucleotide that has been developed to target expanded CAG repeats in messenger ribonucleic acid (mRNA) | Des.TrialAppr. |
| Huntington disease-like 1 | an antisense oligonucleotide that has been developed to target expanded CAG repeats in messenger ribonucleic acid (mRNA) | Des.TrialAppr. |
| Huntington disease-like 2 | an antisense oligonucleotide that has been developed to target expanded CAG repeats in messenger ribonucleic acid (mRNA) | Des.TrialAppr. |
| cerebellar ataxia | 2'-O-methylphosphorothioate RNAoligonucleotide, 5'- m5CUGm5CUGm5CUGm5CUGm5CUGm5CUGm5CUG-3'" | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
15
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
15
overlap in 2+ diseases
0/4
candidate diseases
0
avg importance: 0
0
affecting portfolio